Weekly Spotlight - 27.11.24

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

Latest News

Vatiquinone Does Not Increase Cardiac Risk in FA Patients, Study Finds

A study found that vatiquinone, a potential treatment for friedreich's ataxia, is not likely to increase cardiac risk in patients. The research aimed to assess the safety of vatiquinone, particularly focusing on its impact on heart health, and concluded it is safe in this regard.

New Funding Aims to Improve Understanding of Drug for Rare Genetic Disorder

Researchers have received funding to better understand and develop drugs for Friedreich's ataxia, a genetic disorder that affects balance and movement. The funds will support studies on the disease's mechanisms and potential treatments, aiming to improve the lives of those affected by Friedreich's ataxia.

Navigating Life's Changes with Resilience Despite FA Challenges

Living with Friedreich's ataxia requires adapting to changing goals and finding new ways to achieve them. The article discusses the importance of resilience, flexibility, and redefining success as the disease progresses, emphasizing the need to focus on what can still be accomplished and finding joy in the journey.

Omaveloxolone Shows Positive Long-Term Safety in Ataxia Patients, Says David Lynch

Researchers discuss the long-term safety and efficacy of omaveloxolone, a potential treatment for friedreich's ataxia, highlighting its positive safety profile and potential benefits for patients with this condition. The study emphasizes the drug's ability to improve mitochondrial function and reduce oxidative stress.